TW202317470A - 表面改質奈米粒子 - Google Patents

表面改質奈米粒子 Download PDF

Info

Publication number
TW202317470A
TW202317470A TW111121637A TW111121637A TW202317470A TW 202317470 A TW202317470 A TW 202317470A TW 111121637 A TW111121637 A TW 111121637A TW 111121637 A TW111121637 A TW 111121637A TW 202317470 A TW202317470 A TW 202317470A
Authority
TW
Taiwan
Prior art keywords
group
aforementioned
modified nanoparticles
dnd
boron
Prior art date
Application number
TW111121637A
Other languages
English (en)
Chinese (zh)
Inventor
西川正浩
小松直樹
Original Assignee
國立大學法人京都大學
日商大賽璐股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 國立大學法人京都大學, 日商大賽璐股份有限公司 filed Critical 國立大學法人京都大學
Publication of TW202317470A publication Critical patent/TW202317470A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B32/00—Carbon; Compounds thereof
    • C01B32/25—Diamond
    • C01B32/28—After-treatment, e.g. purification, irradiation, separation or recovery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Ceramic Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111121637A 2021-06-11 2022-06-10 表面改質奈米粒子 TW202317470A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021098083 2021-06-11
JP2021-098083 2021-06-11

Publications (1)

Publication Number Publication Date
TW202317470A true TW202317470A (zh) 2023-05-01

Family

ID=84424595

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111121637A TW202317470A (zh) 2021-06-11 2022-06-10 表面改質奈米粒子

Country Status (6)

Country Link
US (1) US20240277848A1 (https=)
EP (1) EP4353680A4 (https=)
JP (1) JPWO2022260136A1 (https=)
CN (1) CN117460698A (https=)
TW (1) TW202317470A (https=)
WO (1) WO2022260136A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7793185B2 (ja) * 2022-01-19 2026-01-05 国立大学法人金沢大学 修飾ナノダイヤモンドの製造方法
CN119173267A (zh) * 2022-05-20 2024-12-20 国立大学法人京都大学 表面修饰纳米金刚石
WO2025117963A1 (en) * 2023-11-30 2025-06-05 1S1 Energy, Inc. Boronic acid-functionalized carbon materials
WO2026005041A1 (ja) * 2024-06-28 2026-01-02 ＲａｄｉｏＮａｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ株式会社 改変された修飾炭化ホウ素粒子およびそれを含む中性子捕捉療法用薬剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5345771B2 (ja) 2007-08-27 2013-11-20 公立大学法人大阪府立大学 ｐ−ボロノフェニルアラニンとソルビトールとを含有する液状組成物
JP5399118B2 (ja) 2009-04-13 2014-01-29 株式会社ダイセル 表面修飾ナノダイヤモンド及びその製造法
JP5614643B2 (ja) 2010-10-12 2014-10-29 国立大学法人滋賀医科大学 サイズ制御された表面修飾ナノダイヤモンド
CN103877940B (zh) * 2012-12-19 2016-02-10 中国科学院大连化学物理研究所 4-巯基苯硼酸固定化氧化石墨烯复合纳米材料及制备和应用
CN103043647A (zh) * 2012-12-26 2013-04-17 复旦大学 表面修饰氨基苯硼酸的纳米碳材料及其制备方法和应用
JP6316011B2 (ja) * 2014-02-04 2018-04-25 国立大学法人滋賀医科大学 抗癌剤が担持されたナノ粒子
JP6281991B2 (ja) * 2014-04-11 2018-02-21 国立研究開発法人産業技術総合研究所 ホウ素化合物を内包および外壁に担持するカーボンナノホーン及びその製造方法
EP3751021A4 (en) * 2018-02-08 2021-11-10 Daicel Corporation VENEER FILM
US11065334B2 (en) * 2018-11-13 2021-07-20 Uchicago Argonne, Llc Boron-10 containing biocompatible nanostructures
WO2020246500A1 (ja) * 2019-06-05 2020-12-10 株式会社ダイセル 表面修飾ナノダイヤモンド及び表面修飾ナノダイヤモンドの製造方法
WO2021039521A1 (ja) 2019-08-30 2021-03-04 株式会社ダイセル 表面修飾ナノダイヤモンドの製造法
JP6889937B2 (ja) 2019-10-15 2021-06-18 株式会社コナミアミューズメント 抽選装置
CN110812490A (zh) * 2019-11-19 2020-02-21 南京智能高端装备产业研究院有限公司 棒状前药自递送系统及其制备方法和应用
CN119173267A (zh) * 2022-05-20 2024-12-20 国立大学法人京都大学 表面修饰纳米金刚石

Also Published As

Publication number Publication date
US20240277848A1 (en) 2024-08-22
WO2022260136A1 (ja) 2022-12-15
EP4353680A4 (en) 2026-04-22
CN117460698A (zh) 2024-01-26
EP4353680A1 (en) 2024-04-17
JPWO2022260136A1 (https=) 2022-12-15

Similar Documents

Publication Publication Date Title
TW202317470A (zh) 表面改質奈米粒子
US8476386B2 (en) Hyperbranched polymers and their applications
US9745273B2 (en) Phenazine derivatives as anti-neoplastic agents and anti-infective agents
Kang et al. pH-responsive dendritic polyrotaxane drug-polymer conjugates forming nanoparticles as efficient drug delivery system for cancer therapy
CN110872324A (zh) 奥沙利铂偶联前药、其制备方法及用途
Kuang et al. Double pH-responsive supramolecular copolymer micelles based on the complementary multiple hydrogen bonds of nucleobases and acetalated dextran for drug delivery
CN111467500A (zh) 一种低氧双靶向性agt抑制剂偶联物及其制备方法与应用
CN106074379A (zh) 聚乙二醇化奥沙利铂前药及其制备方法和用途
Zhu et al. A novel host-guest complex based on biotin functionalized polyamine-β-cyclodextrin for tumor targeted delivery of luteolin
CN110590855B (zh) 铂类配合物的制备方法及其含有该铂类配合物的脂质体与制备方法
JP2011173960A (ja) 高分子ミセル型光刺激応答性一酸化窒素供与体
Fatykhova et al. Gallic acid-based dendrimers with a thiacalix [4] arene core: synthesis, aggregation and use for stabilization of Pd nanoparticles
AU2020386169A1 (en) Theranostic system for directed diffusion of therapeutic and imaging agents to cancer cells
TW202408546A (zh) 表面改質奈米鑽石
CN110157000B (zh) 生物相容性磁性材料
Brozek et al. Silica nanoparticles carrying boron-containing polymer brushes
CN111789964A (zh) 具有还原响应性的硒类聚合物前药胶束、制备方法和应用
Zhang et al. Stable stereocomplex micelles from Y-shaped amphiphilic copolymers MPEG–(scPLA) 2: Preparation and characteristics
CN113952464B (zh) 含酮羰基的疏水性抗肿瘤药物及其应用
Bhattacharyya et al. Synthesis of 1, 2, 3-triazole linked 5 fluorouracil-carbon dots-folate conjugates for target specific anticancer activity and cell imaging applications
CN107073035B (zh) 治疗铁缺乏的方法
Xiang et al. Linear cyclen-based polyamine as a novel and efficient reagent in gene delivery
CN116063354A (zh) 一种还原响应化疗-免疫治疗前药、纳米胶束及制备方法
CN115141309B (zh) 一种可特异性清除nadph的聚合物、多功能纳米药物及制备方法和应用
Li et al. Self-assembly of nanoparticles from cyclotriphosphazenes grafted with hexa-[p-(carbonyl tryptophan ethyl ester) phenoxy)] group